Latest Breaking News On - American society of nephrology kidney week - Page 1 : comparemela.com

Pegcetacoplan Offers Potential Benefit in Post-Transplant C3G, IC-MPGN

The phase 2 NOBLE trial shows pegcetacoplan reduces disease activity in post-transplant C3G and IC-MPGN, with benefits persisting through the 40-week double-blind period.

How Vertex became the VIP of Alpine's exclusive data room

Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results

Enrolled 12 participants in Phase 2 BESTOW trial evaluating tegoprubart for the prevention of kidney rejection

FDA Grants Orphan Drug Designation to Felzartamab for Kidney Transplant Recipients

Previously, felzartamab received orphan drug designation and breakthrough therapy designation for the treatment of primary membranous nephropathy.

Ardelyx Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

22.02.2024 - Strong commercial performance of IBSRELA continues, ending FY 2023 with $80.1 million in net product sales revenue; 2024 net product sales revenue currently expected to be between $140.0 to $150.0 million XPHOZAH launch off to a strong start, .